Covalon to Present SurgiClear™ at AORN Surgical Conference and Expo

MISSISSAUGA, ON, April 1, 2016 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will be featuring SurgiClear™ at the Association of periOperative Registered Nurse's (AORN) Surgical Conference and Expo, the largest international gathering of perioperative registered nurses worldwide.

SurgiClear™ is one of the most advanced post-operative dressings on the market because of its patent pending dual antimicrobial clear silicone adhesive. SurgiClear's combination of chlorhexidine and silver is proven to have a synergistic effect against some of the most common surgical site infection bacteriaⁱ and SurgiClear's soft silicone adhesive will not cause adhesive related skin injury or pain during dressing changesⁱⁱ.

Covalon will also be showcasing its dual antimicrobial clear silicone adhesive securement dressing IV Clear™, as well as its MediClear™ line of post-op incision and scar management dressings.

"We are delighted about the opportunity to engage with perioperative clinicians regarding the benefits that SurgiClear can bring to both their patients and practice." said John R. Hands, Covalon's Executive Vice President. "Clinicians who have used SurgiClear for more than 15 months have communicated to us experiences such as reduced surgical site infections and lower antibiotic use which is very exciting.  We look forward to presenting all the benefits of our surgical dressings  at AORN." he continued.

In addition to exhibiting, Covalon will be presenting two scientific posters at AORN entitled Novel PreOperative Skin Preparation: Eliminating the "Patient Compliance" Problem and Post-operative Wound Care: The Effect of Variability in Exudate Flow Rate on Dressing Uptake in an in Vitro Wound Model.

Visit Covalon at booth 228 at the AORN Surgical Conference and Expo on April 3-5 at the Anaheim Convention Centre.

About Covalon
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

_____________________________

ⁱ A Laboratory Study of the Synergistic Effect of Chlorhexidine and Silver, Blom, Kristina Werthen, Maria et al. American Journal of Infection Control , Volume 43 , Issue 6 , S22

ⁱⁱ A Human Repeat Patch Test Study, DiTizio et al.http://www.wounds-uk.com/case-series/harrogate-2014-conference-posters

SOURCE Covalon Technologies Ltd.

To learn more about Covalon, please contact: Brian Pedlar, CEO, Covalon Technologies Ltd., Email: [email protected], Phone: [phone] x 233, Toll free: 1.877.711.6055, Web site: www.covalon.com, Twitter: @covalon